Lipid-lowering effects of ezetimibe and simvastatin in combination

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 2, 2011, Pages 131-145

  Ijioma, Nkechinyere ^a   Robinson, Jennifer G ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b Lipid Research Clinic   (United States)

Author keywords

ezetimibe; ezetimibe simvastatin; hyperlipidemia; LDL cholesterol; simvastatin

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CARBAMAZEPINE; COLESEVELAM; COLESTYRAMINE; CYCLOSPORIN; DILTIAZEM; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; NICOTINIC ACID; PLACEBO; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERAPAMIL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AORTA VALVE STENOSIS; ARTICLE; ATHEROSCLEROSIS; AUTOSOMAL RECESSIVE DISORDER; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; DYSLIPIDEMIA; FETUS DISEASE; HEART GRAFT; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MEDLINE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); MUSCLE DISEASE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLEIOTROPY; POSTMARKETING SURVEILLANCE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SITOSTEROLEMIA; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG COMBINATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; SIMVASTATIN;

EID: 79952155957     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.179     Document Type: Article

References (182)

1. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J. Lipid Res. 46(2), 179-190 (2005). (Pubitemid 40271080)
2. Steinberg D. Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia. J. Lipid Res. 46(10), 2037-2051 (2005). (Pubitemid 41377456)
3. Stamler J, Neaton JD. The Multiple Risk Factor Intervention Trial (MRFIT) - importance then and now. JAMA 300(11), 1343-1345 (2008).
4. Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370 (9602), 1829-1839 (2007).
5. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin. Ther. 31(2), 236-244 (2009).
6. Amarenco P, Goldstein LB, Szarek M et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 38(12), 3198-3204 (2007). (Pubitemid 350175737)
7. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J. Am. Coll. Cardiol. 54(25), 2358-2362 (2009).
8. LaRosa JC, Deedwania PC, Shepherd J et al. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am. J. Cardiol. 105(3), 283-287 (2010)
9. de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292(11), 1307-1316 (2004). (Pubitemid 39223221)
10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002).
11. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. 44(3), 720-732 (2004).
12. Smith SC Jr, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19), 2363-2372 (2006). (Pubitemid 43947981)
13. Brunzell JD, Davidson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J. Am. Coll. Cardiol. 51(15), 1512-1524 (2008). (Pubitemid 351470037)
14. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 14(Suppl. 2), S1-S113 (2007). (Pubitemid 47339826)
15. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359(21), 2195-2207 (2008).
16. No authors listed. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934), 1383-1389 (1994).
17. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7-22 (2002).
18. Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. JAMA 302(19), 2104-2110 (2009).
19. Laforest L, Moulin P, Souchet T et al. Correlates of LDL-cholesterol goal attainment in patients under lipid lowering therapy. Atherosclerosis 199(2), 368-377 (2008).
20. Davidson MH, Maki KC, Pearson TA et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology(NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am. J. Cardiol. 96(4), 556-563 (2005). (Pubitemid 41132774)
21. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14), 1425-1435 (2005). (Pubitemid 40471450)
22. Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294(19), 2437-2445 (2005). (Pubitemid 41627921)
23. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc. Drugs Ther. 19(6), 403-414 (2005). (Pubitemid 43228152)
24. Davidson M, Robinson JG. Safety of aggressive lipid management. J. Am. Coll. Cardiol. 49, 1753-1762 (2007). (Pubitemid 46617861)
25. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J. Am. Coll. Cardiol. 48(3), 438-445 (2006). (Pubitemid 44109954)
26. Jacobson TA. Toward 'pain-free' statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin. Proc. 83(6), 687-700 (2008). (Pubitemid 351810569)
27. Bays HE, Goldberg RB. The 'forgotten' bile acid sequestrants: is now a good time to remember? Am. J. Ther. 14(6), 567-580 (2007). (Pubitemid 350307694)
28. Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundam. Clin. Pharmacol. 24(1), 19-28 (2010).
29. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Curr. Med. Res. Opin. 24(4), 995-1009 (2008). (Pubitemid 351579156)
30. Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin. Pharmacother. 8(15), 2569-2578 (2007). (Pubitemid 350031294)
31. Davidson MH, Rosenson RS. Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am. J. Cardiol. 104(10 Suppl.), 52E-57E (2009).
32. Robinson JG. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin. Vasc. Health Risk Manag. 5(1), 31-43 (2009).
33. Paolini JF, Mitchel YB, Reyes R et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am. J. Cardiol. 101(5), 625-630 (2008).
34. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210(2), 353-361 (2010).
35. Wierzbicki AS. Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Curr. Opin. Cardiol. 24(4), 372-379 (2009).
36. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease - a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am. Heart J. 154(5), 943-953 (2007). (Pubitemid 350001283)
37. Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med. 362(17), 1563-1574 (2010).
38. McKenney J, Ballantyne CM, Feldman TA et al. LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. MedGenMed 7(3), 3 (2005).
39. Migoya EM, Bergman A, Hreniuk D et al. Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects. Int. J. Clin. Pharmacol. Ther. 44(2), 83-92 (2006). (Pubitemid 43230591)
40. Hoffman WF, Alberts AW, Anderson PS, Chen JS, Smith RL, Willard AK. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. 4. Side chain ester derivatives of mevinolin. J. Med. Chem. 29(5), 849-852 (1986). (Pubitemid 16034699)
41. Vickers S, Duncan CA, Vyas KP et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab. Dispos. 18(4), 476-483 (1990). (Pubitemid 20220972)
42. Prueksaritanont T, Gorham LM, Ma B et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab. Dispos. 25(10), 1191-1199 (1997). (Pubitemid 27446590)
43. Prueksaritanont T, Subramanian R, Fang X et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. 30(5), 505-512 (2002). (Pubitemid 34456970)
44. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983. Atheroscler. Suppl. 5(3), 61-65 (2004).
45. Zapolska-Downar D, Siennicka A, Kaczmarczyk M, Kolodziej B, Naruszewicz M. Simvastatin modulates TNFa-induced adhesion molecules expression in human endothelial cells. Life Sci. 75(11), 1287-1302 (2004). (Pubitemid 38845028)
46. Paumelle R, Staels B. Cross-talk between statins and PPARa in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc. Med. 18(3), 73-78 (2008). (Pubitemid 351626602)
47. Chen H, Ren JY, Xing Y et al. Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. Int. J. Cardiol. 131(3), 313-320 (2009).
48. Tuomisto TT, Lumivuori H, Kansanen E et al. Simvastatin has an anti-inflammatory effect on macrophages via upregulation of an atheroprotective transcription factor, Kruppel-like factor 2. Cardiovasc. Res. 78(1), 175-184 (2008). (Pubitemid 351430960)
49. Kolovou GD, Katerina A, Ioannis V, Cokkinos DV. Simvastatin: two decades in a circle. Cardiovasc. Ther. 26(2), 166-178 (2008). (Pubitemid 351945130)
50. Ferri N, Colombo G, Ferrandi C, Raines EW, Levkau B, Corsini A. Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Arterioscler. Thromb. Vasc. Biol. 27(5), 1043-1049 (2007). (Pubitemid 46641955)
51. Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ 327(7418), 788 (2003). (Pubitemid 37211173)
52. Bell JP. Timing of simvastatin treatment: what about the shift workers? BMJ 328(7432), 168; author reply 168 (2004).
53. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet. 44(5), 467-494 (2005). (Pubitemid 40733733)
54. Temel RE, Tang W, Ma Y et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J. Clin. Invest. 117(7), 1968-1978 (2007). (Pubitemid 47036331)
55. Lammert F, Wang DQ. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology 129(2), 718-734 (2005). (Pubitemid 41096656)
56. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem. 280(13), 12710-12720 (2005).
57. Levy E, Spahis S, Sinnett D et al. Intestinal cholesterol transport proteins: an update and beyond. Curr. Opin. Lipidol. 18(3), 310-318 (2007). (Pubitemid 46743056)
58. Robinson JG, Davidson MH. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev. Cardiovasc. Ther. 4(4), 461-476 (2006). (Pubitemid 44304551)
59. Tsubakio-Yamamoto K, Nishida M, Nakagawa-Toyama Y, Masuda D, Ohama T, Yamashita S. Current therapy for patients with sitosterolemia - effect of ezetimibe on plant sterol metabolism. J. Atheroscler. Thromb. 17(9), 891-900 (2010).
60. Pearson TA, Ballantyne CM, Veltri E et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am. J. Cardiol. 103(3), 369-374 (2009).
61. Bass A, Hinderliter AL, Lee CR. The impact of ezetimibe on endothelial function and other markers of cardiovascular risk. Ann. Pharmacother. 43(12), 2021-2030 (2009).
62. Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am. J. Cardiol. 99, 1706-1713 (2007).
63. Bays H, Rhyne J, Abby S, Lai YL, Jones M. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr. Med. Res. Opin. 22(11), 2191-2200 (2006). (Pubitemid 44789984)
64. Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am. J. Ther. 12(4), 306-310 (2005). (Pubitemid 41391808)
65. Bergman AJ, Burke J, Larson P et al. Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. J. Clin. Pharmacol. 46(3), 328-336 (2006). (Pubitemid 43260320)
66. Almutairi F, Peterson TC, Molinari M, Walsh MJ, Alwayn I, Peltekian KM. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transpl. 15(5), 504-508 (2009).
67. Rodriguez-Ferrero ML, Anaya F. Ezetimibe in the treatment of uncontrolled hyperlipidemia in kidney transplant patients. Transplant. Proc. 40(10), 3492-3495 (2008).
68. Yoon HE, Song JC, Hyoung BJ et al. The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. Korean J. Intern. Med. 24(3), 233-237 (2009).
69. Turk TR, Voropaeva E, Kohnle M et al. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol. Dial. Transplant. 23(1), 369-373 (2008). (Pubitemid 351767400)
70. Feldman T, Koren M, Insull W Jr et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am. J. Cardiol. 93(12), 1481-1486 (2004). (Pubitemid 38749203)
71. Farnier M, Volpe M, Massaad R, Davies MJ, Allen C. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int. J. Cardiol. 102(2), 327-332 (2005). (Pubitemid 40854051)
72. Zubaid M, Shakir DK, Bazargani N et al. Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial. J. Cardiovasc. Med. (Hagerstown) 9(7), 688-693 (2008).
73. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc. 80(5), 587-595 (2005). (Pubitemid 40628813)
74. Hildemann SK, Barho C, Karmann B, Darius H, Bode C. Sustained effects in hypercholesterolaemic patients on combined simvastatin/ezetimibe treatment: observational cohort study in clinical practice. Curr. Med. Res. Opin. 24(10), 2777-2784 (2008).
75. Patel JV, Hughes EA. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Int. J. Clin. Pract. 60(8), 914-921 (2006). (Pubitemid 44082282)
76. Brohet C, Banai S, Alings AM, Massaad R, Davies MJ, Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr. Med. Res. Opin. 21(4), 571-578 (2005). (Pubitemid 40676109)
77. Migdalis I, Efthimiadis A, Pappas S, Alexopoulos D, Vlasserou F, Mikhailidis DP. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr. Med. Res. Opin. 25(10), 2571-2576 (2009).
78. Derosa G, D'Angelo A, Franzetti IG et al. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. J. Clin. Pharm. Ther. 34(3), 267-276 (2009).
79. Rodney RA, Sugimoto D, Wagman B et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in African- American patients with primary hypercholesterolemia. J. Natl Med. Assoc. 98(5), 772-778 (2006).
80. Ose L, Shah A, Davies MJ et al. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Curr. Med. Res. Opin. 22(5), 823-835 (2006). (Pubitemid 43880116)
81. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc. 79(5), 620-629 (2004). (Pubitemid 38580168)
82. Bays HE, Ose L, Fraser N et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin. Ther. 26(11), 1758-1773 (2004). (Pubitemid 40089489)
83. Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40(12), 2125-2134 (2002). (Pubitemid 36005898)
84. Feldman T, Davidson M, Shah A et al. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post hoc analysis of subpopulations from three pooled clinical trials. Clin. Ther. 28(6), 849-859 (2006). (Pubitemid 44062690)
85. Robinson JG, Davidson MH, Shah A et al. Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65-74 and 75 years and older. Aging Health 3, 691-705 (2007).
86. van der Graaf A, Cuffie-Jackson C, Vissers MN et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J. Am. Coll. Cardiol. 52(17), 1421-1429 (2008).
87. Ose L, Johnson-Levonas A, Reyes R et al. A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. Int. J. Clin. Pract. 61(9), 1469-1480 (2007). (Pubitemid 47228600)
88. Masana L, Mata P, Gagne C et al. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin. Ther. 27(2), 174-184 (2005). (Pubitemid 40462010)
89. Bays H, Sapre A, Taggart W, Liu J, Capece R, Tershakovec A. Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr. Med. Res. Opin. 24(10), 2953-2966 (2008).
90. Strony J, Yang B, Hanson ME, Veltri EP. Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study. Curr. Med. Res. Opin. 24(11), 3149-3157 (2008).
91. Kastelein JJ, Akdim F, Stroes ES et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358(14), 1431-1443 (2008). (Pubitemid 351482735)
92. Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 361, 2113-2122 (2009).
93. Howard W. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER-6 HALTS. Nutr. Metab. Cardiovasc. Dis. 20, 295-300 (2010).
94. Zhao XQ, Yuan C, Hatsukami TS et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler. Thromb. Vasc. Biol. 21(10), 1623-1629 (2001). (Pubitemid 34215582)
95. Underhill HR, Yuan C, Zhao XQ et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am. Heart J. 155(3), 584.e1-8 (2008).
96. van Wissen S, Smilde TJ, Trip MD, Stalenhoef AF, Kastelein JJ. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am. J. Cardiol. 95(2), 264-266 (2005). (Pubitemid 40092097)
97. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357(9256), 577-581 (2001). (Pubitemid 32179609)
98. Fleg JL, Mete M, Howard BV et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in Type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J. Am. Coll. Cardiol. 52(25), 2198-2205 (2008).
99. Meaney A, Ceballos G, Asbun J et al. The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) study. J. Clin. Pharmacol. 49(7), 838-847 (2009).
100. Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90(10), 1084-1091 (2002). (Pubitemid 35339435)
101. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105(21), 2469-2475 (2002). (Pubitemid 34568966)
102. Geiss HC, Otto C, Hund-Wissner E, Parhofer KG. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. Atherosclerosis 180(1), 107-112 (2005).
103. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol. 93(12), 1487-1494 (2004). (Pubitemid 38749204)
104. Liska B, Khattab AA, Herrmann L et al. Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets. Herz 33(5), 362-367 (2008).
105. Strony J, Hoffman R, Hanson M, Veltri E. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients. Clin. Ther. 30(12), 2280-2297 (2008)
106. Catapano AL, Davidson MH, Ballantyne CM et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr. Med. Res. Opin. 22(10), 2041-2053 (2006). (Pubitemid 44663409)
107. Farnier M, Averna M, Missault L et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - the IN-CROSS study. Int. J. Clin. Pract. 63(4), 547-559 (2009).
108. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am. Heart J. 149(3), 464-473 (2005). (Pubitemid 40585409)
109. Catapano A, Brady WE, King TR, Palmisano J. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr. Med. Res. Opin. 21(7), 1123-1130 (2005). (Pubitemid 41032704)
110. Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am. J. Cardiol. 99(12), 1706-1713 (2007).
111. Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Curr. Med. Res. Opin. 24(3), 685-694 (2008). (Pubitemid 351428979)
112. Barrios V, Amabile N, Paganelli F et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int. J. Clin. Pract. 59(12), 1377-1386 (2005). (Pubitemid 43922623)
113. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107(19), 2409-2415 (2003). (Pubitemid 36605221)
114. Assmann G, Kannenberg F, Ramey DR, Musliner TA, Gutkin SW, Veltri EP. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr. Med. Res. Opin. 24(1), 249-259 (2008). (Pubitemid 351160257)
115. Jakulj L, Vissers MN, Groen AK et al. Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial. J. Lipid Res. 51(4), 755-762 (2010).
116. Lakoski SG, Xu F, Vega GL et al. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J. Clin. Endocrinol. Metab. 95(2), 800-809 (2010).
117. McKenney JM, Jones PH, Bays HE et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 192(2), 432-437 (2007). (Pubitemid 46726341)
118. Fazio S, Guyton JR, Polis AB et al. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am. J. Cardiol. 105(4), 487-494 (2010).
119. Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J. Am. Coll. Cardiol. 51(16), 1564-1572 (2008). (Pubitemid 351509420)
120. Farnier M, Roth E, Gil-Extremera B et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am. Heart J. 153(2), 335.e1-8 (2007).
121. Farnier M, Perevozskaya I, Taggart WV, Kush D, Mitchel YB. VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J. Lipid Res. 49(12), 2641-2647 (2008).
122. Tribble DL, Farnier M, Macdonell G et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 57(6), 796-801 (2008). (Pubitemid 351697911)
123. Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin. Ther. 29(11), 2419-2432 (2007).
124. Williams PT, Superko HR, Haskell WL et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler. Thromb. Vasc. Biol. 23(2), 314-321 (2003). (Pubitemid 36231946)
125. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur. Heart J. 31(13), 1633-1639 (2010).
126. Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359(13), 1343-1356 (2008).
127. Wierzbicki AS, Viljoen A, Chambers JB. Aortic stenosis and lipids: does intervention work? Curr. Opin. Cardiol. 25(4), 379-384 (2010).
128. Holme I, Boman K, Brudi P et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am. J. Cardiol. 105(12), 1802-1808 (2010).
129. Landray M, Baigent C, Leaper C et al. The Second United Kingdom Heart and Renal Protection (UK-HARP-II) study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am. J. Kidney Dis. 47(3), 385-395 (2006). (Pubitemid 43255171)
130. Cannon CP, Giugliano RP, Blazing MA et al. Rationale and design of IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am. Heart J. 156(5), 826-832 (2008).
131. Lindenfeld J, Page RL 2nd, Zolty R et al. Drug therapy in the heart transplant recipient: part III: common medical problems. Circulation 111(1), 113-117 (2005). (Pubitemid 40070852)
132. Chamorro CI, Almenar L, Martinez-Dolz L et al. Do cardiovascular risk factors influence cardiac allograft vasculopathy? Transplant. Proc. 38(8), 2572-2574 (2006). (Pubitemid 44693692)
133. Moro J, Almenar L, Martinez-Dolz L et al. Ezetimibe in heart transplantation: initial experience. Transplant. Proc. 39(7), 2389-2392 (2007). (Pubitemid 47418152)
134. Quarta CC, Potena L, Grigioni F et al. Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients. J. Heart Lung Transplant. 27(6), 685-688 (2008).
135. Gaudiani LM, Lewin A, Meneghini L et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated Type 2 diabetic patients. Diabetes Obes. Metab. 7(1), 88-97 (2005).
136. Hildemann SK, Barho C, Karmann B, Darius H, Bestehorn K. Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr. Med. Res. Opin. 23(4), 713-719 (2007). (Pubitemid 46631474)
137. Goldberg RB, Guyton JR, Mazzone T et al. Ezetimibe/simvastatin vs atorvastatin in patients with Type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin. Proc. 81(12), 1579-1588 (2006). (Pubitemid 44871902)
138. Constance C, Westphal S, Chung N et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with Type 2 diabetes mellitus. Diabetes Obes. Metab. 9(4), 575-584 (2007). (Pubitemid 47018521)
139. Howard BV, Roman MJ, Devereux RB et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 299(14), 1678-1689 (2008). (Pubitemid 351519865)
140. Ruggenenti P, Cattaneo D, Rota S et al. Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with Type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care 33(9), 1954-1956 (2010).
141. Winkler K, Schewe T, Putz G et al. Fluvastatin/fenofibrate vs. simvastatin/ ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur. J. Clin. Invest. 39(6), 463-470 (2009).
142. Robinson JG, Ballantyne CM, Grundy SM et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am. J. Cardiol. 103(12), 1694-1702 (2009).
143. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FL. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 202(1), 216-224 (2009).
144. Chenot F, Montant PF, Marcovitch O, Blaimont M, de Meester A, Descamps OS. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Eur. J. Clin. Invest. 37(5), 357-363 (2007). (Pubitemid 46656104)
145. Reckless JP, Henry P, Pomykaj T et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int. J. Clin. Pract. 62(4), 539-554 (2008). (Pubitemid 351348028)
146. Kohnle M, Pietruck F, Kribben A, Philipp T, Heemann U, Witzke O. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am. J. Transplant. 6(1), 205-208 (2006). (Pubitemid 43382220)
147. Araujo DB, Bertolami MC, Ferreira WP et al. Pleiotropic effects with equivalent low-density lipoprotein cholesterol reduction: comparative study between simvastatin and simvastatin/ezetimibe coadministration. J. Cardiovasc. Pharmacol. 55(1), 1-5 (2010).
148. Efrati S, Averbukh M, Dishy V, Faygenzo M, Friedensohn L, Golik A. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J. Clin. Pharmacol. 63(2), 113-121 (2007). (Pubitemid 46147052)
149. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 119(1), 131-138 (2009).
150. Fichtlscherer S, Schmidt-Lucke C, Bojunga S et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur. Heart J. 27(10), 1182-1190 (2006).
151. Settergren M, Bohm F, Ryden L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur. Heart J. 29(14), 1753-1760 (2008). (Pubitemid 352019812)
152. Olijhoek JK, Hajer GR, van der Graaf Y, Dallinga-Thie GM, Visseren FL. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J. Cardiovasc. Pharmacol. 52(2), 145-150 (2008).
153. Westerweel PE, Visseren FL, Hajer GR et al. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. Eur. Heart J. 29(22), 2808-2817 (2008).
154. Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. J. Am. Coll. Cardiol. 49(7), 741-752 (2007).
155. Kater AL, Batista MC, Ferreira SR. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism 59(6), 921-926 (2010).
156. Hussein O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J. Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br. J. Clin. Pharmacol. 65(5), 637-645 (2008). (Pubitemid 351535082)
157. Tremblay AJ, Lamarche B, Hogue JC, Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J. Lipid Res. 50(7), 1463-1471 (2009).
158. Sudhop T, Reber M, Tribble D et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J. Lipid Res. 50, 2117-2123 (2009).
159. Gouni-Berthold I, Berthold HK, Gylling H et al. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis 198(1), 198-207 (2008). (Pubitemid 351406373)
160. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res. 49(2), 394-398 (2008). (Pubitemid 351213624)
161. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J. Lipid Res. 51(9), 2714-2721 (2010).
162. Mayne J, Dewpura T, Raymond A et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 7, 22 (2008).
163. Berthold HK, Naini A, Di Mauro S et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf. 29(8), 703-712 (2006). (Pubitemid 44175041)
164. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann. Intern. Med. 150(12), 858-868 (2009).
165. Gouni-Berthold I, Berthold HK, Chamberland JP, Krone W, Mantzoros CS. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin. Endocrinol. (Oxf.) 68(4), 536-541 (2008). (Pubitemid 351388705)
166. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Olijhoek JK, Visseren FL. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-C) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial. Clin. Endocrinol. (Oxf.) 69(6), 870-877 (2008).
167. Bakhai A. Adipokines - targeting a root cause of cardiometabolic risk. QJM 101(10), 767-776 (2008).
168. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J. Am. Coll. Cardiol. 49, 2003-2009 (2007). (Pubitemid 46734641)
169. Sager PT, Capece R, Lipka L et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 179(2), 361-367 (2005). (Pubitemid 40364632)
170. Killilea T, Funk L. Cost efficiency and formulary considerations for statin therapy. Am. J. Manag. Care 12(11 Suppl.), S325-S331 (2006). (Pubitemid 44683780)
171. Soini EJ, Davies G, Martikainen JA, Hu HX, Tunceli K, Niskanen L. Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr. Med. Res. Opin. 26(1), 25-36 (2010).
172. Nherera L, Calvert NW, Demott K et al. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr. Med. Res. Opin. 26(3), 529-536 (2010).
173. Sharma M, Ansari MT, Abou-Setta AM et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann. Intern. Med. 151(9), 622-630 (2009).
174. Davidson MH, Maccubbin D, Stepanavage M, Strony J, Musliner T. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am. J. Cardiol. 97(2), 223-228 (2006). (Pubitemid 43139240)
175. Peto R, Emberson J, Landray M et al. Analyses of cancer data from three ezetimibe trials. N. Engl. J. Med. 359(13), 1357-1366 (2008).
176. Halleck M, Davis HR, Kirschmeier P et al. An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach. Toxicology. 258(2-3), 116-130 (2009).
177. Ridker PM, Danielson E, Fonseca FAH et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
178. Howard WJ. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS. Nutr. Metab. Cardiovasc. Dis. 20(5), 295-300 (2010).
179. Robinson JG. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk. Am. J. Cardiol. 101, 1009-1015 (2008).
180. Holme I, Boman K, Brudi P et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis Trial. Am. J. Cardiol. 105(12), 1802-1808 (2010).
181. Roberts MD. Crestor (rosuvastatin calcium) NDA 21-336 JUPITER. Presented at: US Food and Drug Administration, Endocrinologic and Metabolic Drugs Advisory Meeting. Gaithersburg, MD, USA, 15 July 2009.
182. Robinson JG, Stone NJ. Identifying patients for aggressive cholesterol lowering: the risk curve concept. Am. J. Cardiol. 98, 1405-1408 (2006).(Pubitemid 44666653)